- Home
- BRT vs AARD Comparison
BRT vs AARD Comparison
Compare BRT & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | AARD |
|---|---|---|
| Founded | 1972 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.9M | 297.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | BRT | AARD |
|---|---|---|
| Price | $14.63 | $13.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $19.75 | ★ $31.11 |
| AVG Volume (30 Days) | 36.6K | ★ 184.5K |
| Earning Date | 03-11-2026 | 03-31-2026 |
| Dividend Yield | ★ 6.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $98,001,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.30 | N/A |
| 52 Week Low | $14.00 | $4.88 |
| 52 Week High | $19.01 | $19.58 |
Technical Indicators
Market Signals| Indicator | BRT | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 40.84 |
| Support Level | $14.33 | $12.43 |
| Resistance Level | $14.81 | $15.11 |
| Average True Range (ATR) | 0.29 | 1.11 |
| MACD | -0.03 | -0.32 |
| Stochastic Oscillator | 34.88 | 15.32 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.